One in six people in the UK has already received care from a clinician using Semble’s platform, without most of them ever knowing the software existed. That kind of quiet infrastructure scale, 10 million patients across 1,700 healthcare businesses, is exactly what convinced a new set of European growth investors that the company’s next move is worth backing.
London-based Semble has secured a £30 million Series C led by Paris-headquartered European growth investor Revaia, with participation from new investor Partech and returning backers Mercia Ventures and Octopus Ventures. The round brings Semble’s total funding to approximately £57 million, nearly doubling its capitalisation since the £11.5 million Series B it closed in October 2024.
What Semble does
Founded in 2016 by Christoph Lippuner and Mikael Landau – both second-time founders who previously built and exited a startup together – Semble began life as Heydoc before rebranding. Lippuner previously spent 11 years as an Executive Director at J.P. Morgan and co-founded Orogo before turning to healthcare technology. The company is headquartered in London with offices in Paris.
The problem Semble targets is structural. Private outpatient healthcare – clinics, specialist practices, hospital groups – typically runs on fragmented software: one system for scheduling, another for billing, a third for clinical records, and often none that talk to each other. The British Medical Association has estimated that doctors in England lose 13.5 million working hours a year to inadequate IT systems alone. Semble consolidates these functions into a single platform covering scheduling, billing, clinical records, reporting, prescriptions, and patient communications, and integrates with more than 1,200 external tools including diagnostics, labs, and CRM systems.
